Market Cap 144.92M
Revenue (ttm) 1.23M
Net Income (ttm) -28.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,326.83%
Debt to Equity Ratio 0.00
Volume 749,300
Avg Vol 1,400,734
Day's Range N/A - N/A
Shares Out 36.23M
Stochastic %K 90%
Beta 2.14
Analysts Strong Sell
Price Target $39.67

Company Profile

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100,...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 254 6134
Address:
1201 N. Market Street, Suite 111, Wilmington, United States
dcrmia
dcrmia Jul. 1 at 4:27 PM
$NRXP Coming...🚀🔋
0 · Reply
nick_m
nick_m Jul. 1 at 4:20 PM
$NRXP this is only for value long term investors 🚀🚀🚀
0 · Reply
retired24
retired24 Jul. 1 at 4:19 PM
$NRXP 4 weeks away from the FDA decision
0 · Reply
fuctonfauci
fuctonfauci Jul. 1 at 3:47 PM
$NRXP Business as usual: management is creating value for short sellers and institutions.
0 · Reply
texmade2
texmade2 Jul. 1 at 2:55 PM
$NRXP 3.70 looks right
0 · Reply
Chumpchange53
Chumpchange53 Jul. 1 at 10:37 AM
$NRXP $NRX Pharmaceuticals Inc NRx Pharmaceuticals On July 29, 2026, the FDA is scheduled to announce its decision on NRx Pharmaceuticals, Inc.’s (NRXP) Abbreviated New Drug Application (ANDA) for KETAFREE. KETAFREE is a preservative-free intravenous ketamine formulation intended for all currently approved ketamine indications and manufactured in the United States, supporting national efforts to strengthen the domestic supply of critical medicines. Current ketamine products are typically supplied in multi-dose vials that contain a preservative called Benzethonium Chloride (BZT) that is not recognized as safe by the FDA and is banned from hand cleansers and topical antiseptics. NRXP closed Tuesday’s (June 30, 2026) trading at $4.09, up 2.25%.
1 · Reply
Rolo2024
Rolo2024 Jul. 1 at 4:34 AM
$NRXP We have huge potential catalyst that can let NRXP rip upwards and investors dump their shares on a news article about a lawsuit?! Who do you think bought you cheap shares?
0 · Reply
surfsup11
surfsup11 Jul. 1 at 2:58 AM
$NRXP So you have invested 25,000 shares at what 3.00 a share so 75,000$ in a con artist. Better have your head checked? Talk about pins and needles every morning at 7am???🤣
1 · Reply
jonny80s
jonny80s Jun. 30 at 7:36 PM
$NRXP I understand the NDA missing. I’ve known Javitt has never had the right trial data for years. But to misslead investors concerning the clinic acquisitions as well is a terrible look. 0 accountability from Javitt and his executive team: who don’t have much, if any, of stake in the organization.
2 · Reply
Starwanderer
Starwanderer Jun. 30 at 6:25 PM
$NRXP Less than 2 weeks to wait. If until mid-July the FDA doesn't come up with an extension of the examination period for some reason, the approval could seem very likely. The thing is that when the FDA has an issue with an application, they extend the examination period. They may do so even a few weeks before the target date. But if they don't, and I think that middle of July may be a fair deadline for announcing an extension, then - long live the FOMO.
0 · Reply
Latest News on NRXP
NRx Pharmaceuticals issues response to Kadima statements

2026-06-25T20:15:31.000Z - 5 days ago

NRx Pharmaceuticals issues response to Kadima statements


NRx Pharmaceuticals 5.7M share Spot Secondary priced at $3.50

2026-06-03T15:17:33.000Z - 4 weeks ago

NRx Pharmaceuticals 5.7M share Spot Secondary priced at $3.50


NRx Pharmaceuticals Earnings Call Transcript: Q1 2026

May 18, 2026, 8:00 AM EDT - 6 weeks ago

NRx Pharmaceuticals Earnings Call Transcript: Q1 2026


NRx Pharmaceuticals Quarterly report: Q1 2026

May 18, 2026, 8:00 AM EDT - 6 weeks ago

NRx Pharmaceuticals Quarterly report: Q1 2026


NRx Pharmaceuticals Earnings release: Q1 2026

May 18, 2026, 8:00 AM EDT - 6 weeks ago

NRx Pharmaceuticals Earnings release: Q1 2026


NRx Pharmaceuticals initiated with a Buy at Lucid Capital

2026-05-13T10:11:36.000Z - 7 weeks ago

NRx Pharmaceuticals initiated with a Buy at Lucid Capital


NRx Pharmaceuticals gets FDA feedback on ketamine program

2026-04-22T11:48:51.000Z - 2 months ago

NRx Pharmaceuticals gets FDA feedback on ketamine program


NRx Pharmaceuticals welcomes the newly-signed Executive Order

2026-04-20T11:20:02.000Z - 2 months ago

NRx Pharmaceuticals welcomes the newly-signed Executive Order


NRx Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 24, 2026, 8:00 AM EDT - 3 months ago

NRx Pharmaceuticals Earnings Call Transcript: Q4 2025


NRx Pharmaceuticals Earnings release: Q4 2025

Mar 24, 2026, 8:00 AM EDT - 3 months ago

NRx Pharmaceuticals Earnings release: Q4 2025


NRx Pharmaceuticals Annual report: Q4 2025

Mar 24, 2026, 8:00 AM EDT - 3 months ago

NRx Pharmaceuticals Annual report: Q4 2025


NRx Pharmaceuticals Transcript: AGM 2026

Mar 23, 2026, 10:00 AM EDT - 3 months ago

NRx Pharmaceuticals Transcript: AGM 2026


NRx Pharmaceuticals Proxy statement: Proxy Filing

Feb 24, 2026, 7:00 AM EST - 4 months ago

NRx Pharmaceuticals Proxy statement: Proxy Filing


NRx Pharmaceuticals Proxy statement: Proxy Filing

Feb 23, 2026, 7:00 AM EST - 4 months ago

NRx Pharmaceuticals Proxy statement: Proxy Filing


NRx Pharmaceuticals Proxy statement: Proxy Filing

Feb 13, 2026, 7:00 AM EST - 4 months ago

NRx Pharmaceuticals Proxy statement: Proxy Filing


NRx Pharmaceuticals Registration statement: Registration Filing

Dec 12, 2025, 7:00 AM EST - 7 months ago

NRx Pharmaceuticals Registration statement: Registration Filing


NRx Pharmaceuticals Transcript: Study Update

Dec 2, 2025, 9:00 AM EST - 7 months ago

NRx Pharmaceuticals Transcript: Study Update


NRx Pharmaceuticals Press release: Study Update

Dec 2, 2025, 9:00 AM EST - 7 months ago

NRx Pharmaceuticals Press release: Study Update


NRx Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 17, 2025, 8:30 AM EST - 8 months ago

NRx Pharmaceuticals Earnings Call Transcript: Q3 2025


NRx Pharmaceuticals Earnings release: Q3 2025

Nov 17, 2025, 8:30 AM EST - 8 months ago

NRx Pharmaceuticals Earnings release: Q3 2025


NRx Pharmaceuticals Quarterly report: Q3 2025

Nov 17, 2025, 8:30 AM EST - 8 months ago

NRx Pharmaceuticals Quarterly report: Q3 2025


NRx Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 20, 2025, 8:00 AM EDT - 11 months ago

NRx Pharmaceuticals Earnings Call Transcript: Q2 2025


NRx Pharmaceuticals Earnings release: Q2 2025

Aug 20, 2025, 8:00 AM EDT - 11 months ago

NRx Pharmaceuticals Earnings release: Q2 2025


NRx Pharmaceuticals Quarterly report: Q2 2025

Aug 20, 2025, 8:00 AM EDT - 11 months ago

NRx Pharmaceuticals Quarterly report: Q2 2025


dcrmia
dcrmia Jul. 1 at 4:27 PM
$NRXP Coming...🚀🔋
0 · Reply
nick_m
nick_m Jul. 1 at 4:20 PM
$NRXP this is only for value long term investors 🚀🚀🚀
0 · Reply
retired24
retired24 Jul. 1 at 4:19 PM
$NRXP 4 weeks away from the FDA decision
0 · Reply
fuctonfauci
fuctonfauci Jul. 1 at 3:47 PM
$NRXP Business as usual: management is creating value for short sellers and institutions.
0 · Reply
texmade2
texmade2 Jul. 1 at 2:55 PM
$NRXP 3.70 looks right
0 · Reply
Chumpchange53
Chumpchange53 Jul. 1 at 10:37 AM
$NRXP $NRX Pharmaceuticals Inc NRx Pharmaceuticals On July 29, 2026, the FDA is scheduled to announce its decision on NRx Pharmaceuticals, Inc.’s (NRXP) Abbreviated New Drug Application (ANDA) for KETAFREE. KETAFREE is a preservative-free intravenous ketamine formulation intended for all currently approved ketamine indications and manufactured in the United States, supporting national efforts to strengthen the domestic supply of critical medicines. Current ketamine products are typically supplied in multi-dose vials that contain a preservative called Benzethonium Chloride (BZT) that is not recognized as safe by the FDA and is banned from hand cleansers and topical antiseptics. NRXP closed Tuesday’s (June 30, 2026) trading at $4.09, up 2.25%.
1 · Reply
Rolo2024
Rolo2024 Jul. 1 at 4:34 AM
$NRXP We have huge potential catalyst that can let NRXP rip upwards and investors dump their shares on a news article about a lawsuit?! Who do you think bought you cheap shares?
0 · Reply
surfsup11
surfsup11 Jul. 1 at 2:58 AM
$NRXP So you have invested 25,000 shares at what 3.00 a share so 75,000$ in a con artist. Better have your head checked? Talk about pins and needles every morning at 7am???🤣
1 · Reply
jonny80s
jonny80s Jun. 30 at 7:36 PM
$NRXP I understand the NDA missing. I’ve known Javitt has never had the right trial data for years. But to misslead investors concerning the clinic acquisitions as well is a terrible look. 0 accountability from Javitt and his executive team: who don’t have much, if any, of stake in the organization.
2 · Reply
Starwanderer
Starwanderer Jun. 30 at 6:25 PM
$NRXP Less than 2 weeks to wait. If until mid-July the FDA doesn't come up with an extension of the examination period for some reason, the approval could seem very likely. The thing is that when the FDA has an issue with an application, they extend the examination period. They may do so even a few weeks before the target date. But if they don't, and I think that middle of July may be a fair deadline for announcing an extension, then - long live the FOMO.
0 · Reply
Oopsallblueberries
Oopsallblueberries Jun. 30 at 5:30 PM
$NRXP I've trimmed my position from 16k shares all the way down to 2k shares this month. By tomorrow i should know if that was a huge mistake or i avoided getting scammed. Hopefully they follow through on the promises and we rocket up to 10$+, but i doubt it.
2 · Reply
systemish
systemish Jun. 30 at 5:02 PM
$NRXP Hedgies that wrote those July 17 calls right now. Wondering when the next slander piece hits.
0 · Reply
signaljumper
signaljumper Jun. 30 at 4:49 PM
$NRXP lets Close the Gap to 4.58$
0 · Reply
Dubbyy
Dubbyy Jun. 30 at 4:11 PM
0 · Reply
fuctonfauci
fuctonfauci Jun. 30 at 2:23 PM
$NRXP Once again, the honest long-term shareholders don't seem to understand what management means when it repeatedly points to a timeline running through the end of June, or Q2.
1 · Reply
Milan1969
Milan1969 Jun. 30 at 12:55 PM
$NRXP $NRXP – One of the biotech stocks worth watching. The coming months could be pivotal for NRx Pharmaceuticals. Key points investors are watching: • Multiple regulatory and clinical milestones. • Continued progress toward commercialization of its lead programs. • Expansion of strategic partnerships and manufacturing capabilities. • A relatively small market capitalization compared with the potential value if upcoming catalysts are successful. As always with biotech, the risks remain high, but so can the potential rewards if the company delivers on its milestones. Do your own research and follow the upcoming announcements closely. $NRXP #Biotech #Healthcare #Investing #Stocks
0 · Reply
TheRealBomb
TheRealBomb Jun. 30 at 12:32 PM
$NRXP I'm not concerned about a few days plus or minus. Already been here 5 years. Many of you have been here for a while too, especially some repetitive shorts. I'm sure they will come out of the wordwork after today spreading FUD like a Iranian state television network. The NDA will be submitted within due time. If it happens this week, they will await a confirm receipt from FDA before announcing. I've worked with government for over a decade, and I can tell you, nothing moves fast. Beaurocracy slows everything down. Good things come to those who know what they own and have patience. It's all working, slower than many would like, but stop watching the paint dry already. Invest and wait, or move on. We don't need yall weak hands anyway when the real runs begin.
0 · Reply
Bigtuna42
Bigtuna42 Jun. 30 at 11:06 AM
$NRXP not looking like they will be submitting the nda on time. Usually they announce some PR just after 7am est. no news so they are probably delayed.
2 · Reply
Outcomes
Outcomes Jun. 30 at 10:46 AM
$IBRX $MNKD $NRXP ….great morning!!
1 · Reply
Paulisdead
Paulisdead Jun. 29 at 8:03 PM
$NRXP Showed up in my feed: NRx Pharmaceuticals, Inc.(NasdaqCM:NRXP) dropped from Russell 3000E Growth Benchmark Meaningful?
1 · Reply
systemish
systemish Jun. 29 at 7:32 PM
$NRXP so I guess tomorrow morning is the PR detailing the NDA for NRX-100. Really really looking forward to it.
1 · Reply
TheRealBomb
TheRealBomb Jun. 29 at 5:08 PM
$NRXP Faith and Hope! Hold if you want the returns. This will be a multi-billion $ company in the next few years. You can mark this post. Peace!
0 · Reply